

Datasheet: MCA2200D550

Description:	MOUSE ANTI C-MYC:DyLight®550
Specificity:	C-MYC
Format:	DyLight®550
Product Type:	Monoclonal Antibody
Clone:	9E10
Isotype:	IgG1
Quantity:	0.1 mg

Product Details

Applications

This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit www.bio-rad-antibodies.com/protocols.

	Yes	No	Not Determined	Suggested Dilution
Flow Cytometry (1)	▪			Neat
Western Blotting	▪			1/1,000 - 1/2,000
Immunofluorescence	▪			Neat - 1/10

Where this antibody has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the antibody for use in their own systems using appropriate negative/positive controls.

(1) Membrane permeabilisation is required for this application. Bio-Rad recommends the use of Leucoperm™ (Product Code [BUF09](#)) for this purpose.

Target Species	Human		
Species Cross Reactivity	Reacts with: Epitope tag N.B. Antibody reactivity and working conditions may vary between species. Cross reactivity is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information.		
Product Form	Purified IgG conjugated to DyLight®550 - liquid		
Max Ex/Em	Fluorophore	Excitation Max (nm)	Emission Max (nm)
	Dylight®550	562	576
Preparation	Purified IgG prepared by affinity chromatography on Protein G from tissue culture		

supernatant

Buffer Solution	Phosphate buffered saline
------------------------	---------------------------

Preservative Stabilisers	0.09% Sodium Azide (NaN ₃)
---------------------------------	--

Approx. Protein Concentrations	IgG concentration 1.0 mg/ml
---------------------------------------	-----------------------------

Immunogen	Synthetic peptide sequence corresponding to the C-terminal region (residues 408-439) of human c-myc conjugated to keyhole limpet hemocyanin.
------------------	--

External Database Links

UniProt:

[P01106](#) [Related reagents](#)

Entrez Gene:

[4609](#) MYC [Related reagents](#)

Synonyms	BHLHE39
-----------------	---------

Fusion Partners	Spleen cells from immunised BALB/c mice were fused with cells of the SP2/0 myeloma cell line.
------------------------	---

Specificity	<p>Mouse anti c-myc antibody, clone 9E10 detects the p62^{c-myc} proto-oncogene protein, which is involved in the regulation of the cell cycle and cell growth. C-myc is primarily located to the cell nucleus, but has also been shown to localized to the cytoplasm in several cell lines (Craig et al. 1993). Overexpression of c-myc has been reported in a wide variety of human cancers (Nesbit <i>et al.</i> 1999).</p>
--------------------	---

Mouse anti c-myc antibody, clone 9E10 recognizes the sequence EQKLISEEDL and may be used to detect proteins and peptides labelled with molecular tags containing this sequence (Hilpert *et al.* 2001).

References

1. Evan, G.I. *et al.* (1985) Isolation of monoclonal antibodies specific for human c-myc proto-oncogene product. [Mol Cell Biol. 5 \(12\): 3610-6.](#)
2. Spandidos, D.A. *et al.* (1987) Elevated expression of the myc gene in human benign and malignant breast lesions compared to normal tissue. [Anticancer Res. 7 \(6\): 1299-304.](#)
3. Borodina, I. *et al.* (2010) Display of wasp venom allergens on the cell surface of *Saccharomyces cerevisiae*. [Microb Cell Fact. 9: 74.](#)
4. Groeger, G. *et al.* (2007) Co-operative Cdc42 and Rho signalling mediates ephrinB-triggered endothelial cell retraction. [Biochem J. 404: 23-9.](#)
5. Head, B. *et al.* (2009) Inducible proteolytic inactivation of OPA1 mediated by the OMA1 protease in mammalian cells. [J Cell Biol. 187: 959-66.](#)
6. Hilpert, K. *et al.* (2001) Anti-c-myc antibody 9E10: epitope key positions and variability characterized using peptide spot synthesis on cellulose. [Protein Eng. 14: 803-6.](#)
7. Gohlke, S. *et al.* (2017) *In Vitro* and *In Vivo* Studies on the Structural Organization of Chs3 from *Saccharomyces cerevisiae*. [Int J Mol Sci. 18 \(4\): pii: E702.](#)

8. Gray, P. *et al.* (2010) Identification of a novel human MD-2 splice variant that negatively regulates Lipopolysaccharide-induced TLR4 signaling. [J Immunol. 184: 6359-66.](#)
9. Duriseti, S. *et al.* (2010) Antagonistic anti-urokinase plasminogen activator receptor (uPAR) antibodies significantly inhibit uPAR-mediated cellular signaling and migration. [J Biol Chem. 285: 26878-88.](#)
10. Tan, P.H. *et al.* (2005) Creation of tolerogenic human dendritic cells via intracellular CTLA4: a novel strategy with potential in clinical immunosuppression. [Blood. 106: 2936-43.](#)
11. Wallace, S.W. *et al.* (2010) Cdc42 regulates apical junction formation in human bronchial epithelial cells through PAK4 and Par6B. [Mol Biol Cell. 21: 2996-3006.](#)
12. Rowshanravan, B. *et al.* (2014) RasGAP mediates neuronal survival in *Drosophila* through direct regulation of Rab5-dependent endocytosis. [J Cell Sci. 127: 2849-61.](#)
13. Taylor K *et al.* (2015) Nanocell targeting using engineered bispecific antibodies. [MAbs. 7 \(1\): 53-65.](#)
14. Elders, R.C. *et al.* (2014) Recombinant canine IgE Fc and an IgE Fc-TRAIL fusion protein bind to neoplastic canine mast cells. [Vet Immunol Immunopathol. 159 \(1-2\): 29-40.](#)
15. Sharkey, A.M. *et al.* (2015) Tissue-Specific Education of Decidual NK Cells. [J Immunol. 195 \(7\): 3026-32.](#)
16. McGough, I.J. *et al.* (2014) Identification of molecular heterogeneity in SNX27-retromer-mediated endosome-to-plasma-membrane recycling. [J Cell Sci. 127 \(Pt 22\): 4940-53.](#)
17. Frohnert, C. *et al.* (2014) Importin 7 and Nup358 promote nuclear import of the protein component of human telomerase. [PLoS One. 9 \(2\): e88887.](#)
18. Hage, N. *et al.* (2015) Improved expression and purification of the *Helicobacter pylori* adhesin BabA through the incorporation of a hexa-lysine tag. [Protein Expr Purif. 106: 25-30.](#)
19. Mann, J.K. & Park, S. (2015) Epitope-Specific Binder Design by Yeast Surface Display. [Methods Mol Biol. 1319: 143-54.](#)
20. Paraskevopoulou, V. *et al.* (2019) Introduction of a C-terminal hexa-lysine tag increases thermal stability of the LacDiNAc binding adhesin (LabA) exodomain from *Helicobacter pylori*. [Protein Expr Purif. 163: 105446.](#)
21. Lim, H.K. *et al.* (2010) Flow cytometric analysis of genetic FRET detectors containing variable substrate sequences. [Biotechnol Prog. 26 \(6\): 1765-71.](#)
22. Walker, L.M. *et al.* (2009) Efficient recovery of high-affinity antibodies from a single-chain Fab yeast display library. [J Mol Biol. 389 \(2\): 365-75.](#)
23. Matos, J. *et al.* (2013) Cell-cycle kinases coordinate the resolution of recombination intermediates with chromosome segregation. [Cell Rep. 4 \(1\): 76-86.](#)
24. Paraskevopoulou, V. *et al.* (2020) Structural and binding characterization of the LacdiNAc-specific adhesin (LabA; HopD) exodomain from *Helicobacter pylori*. [Curr Res Struct Biol. 15 Dec \[Epub ahead of print\].](#)
25. Kalusche, S. *et al.* (2020) Lactobacilli Expressing Broadly Neutralizing Nanobodies against HIV-1 as Potential Vectors for HIV-1 Prophylaxis? [Vaccines \(Basel\). 8 \(4\) Dec 13 \[Epub ahead of print\].](#)
26. Hollandsworth, H.M. *et al.* (2020) Fluorophore-conjugated *Helicobacter pylori* recombinant membrane protein (HopQ) labels primary colon cancer and metastases in orthotopic mouse models by binding CEA-related cell adhesion molecules. [Transl Oncol. 13 \(12\): 100857.](#)

27. Paraskevopoulou, V. *et al.* (2021) Structural and binding characterization of the LacdiNAc-specific adhesin (LabA; HopD) exodomain from *Helicobacter pylori*. [Curr Res Struct Biol. 3: 19-29.](#)

Further Reading

1. Nesbit, C. *et al.* (1999) MYC oncogenes and human neoplastic disease. [Oncogene. 18: 3004-16.](#)
2. Krauß, N. *et al.* (2008) The structure of the anti-c-myc antibody 9E10 Fab fragment/epitope peptide complex reveals a novel binding mode dominated by the heavy chain hypervariable loops. [Proteins. 73: 552-65.](#)

Storage

This product is shipped at ambient temperature. It is recommended to aliquot and store at -20°C on receipt. When thawed, aliquot the sample as needed. Keep aliquots at 2-8°C for short term use (up to 4 weeks) and store the remaining aliquots at -20°C.

Avoid repeated freezing and thawing as this may denature the antibody. Storage in frost-free freezers is not recommended.

Guarantee 12 months from date of despatch

Acknowledgements DyLight® is a trademark of Thermo Fisher Scientific Inc. and its subsidiaries.

Health And Safety Information Material Safety Datasheet documentation #10040 available at: 10040: <https://www.bio-rad-antibodies.com/uploads/MSDS/10040.pdf>

Regulatory For research purposes only

Related Products

Recommended Useful Reagents

[HUMAN SEROBLOCK \(BUF070A\)](#)

[HUMAN SEROBLOCK \(BUF070B\)](#)

North & South Tel: +1 800 265 7376

America Fax: +1 919 878 3751

Email: antibody_sales_us@bio-rad.com

Worldwide

Tel: +44 (0)1865 852 700

Fax: +44 (0)1865 852 739

Email: antibody_sales_uk@bio-rad.com

Europe

Tel: +49 (0) 89 8090 95 21

Fax: +49 (0) 89 8090 95 50

Email: antibody_sales_de@bio-rad.com

To find a batch/lot specific datasheet for this product, please use our online search tool at: [bio-rad-antibodies.com/datasheets](https://www.bio-rad-antibodies.com/datasheets)

'M395106:220314'

Printed on 19 May 2022

© 2022 Bio-Rad Laboratories Inc | [Legal](#) | [Imprint](#)